Organization
University College Hospital-London
6 abstracts
Abstract
Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression.Org: University of Milan-Bicocca, University of California Los Angeles Medical Center, European Institute of Oncology IRCCS, University of Chicago, ImmunoGen,
Abstract
NEOPRISM-CRC: Neoadjuvant pembrolizumab stratified to tumour mutation burden for high risk stage 2 or stage 3 deficient-MMR/MSI-high colorectal cancer.Org: University College Hospital-London, NHS Foundation Trust, University College London Cancer Institute, The Christie NHS Foundation Trust, University of Leeds,
Abstract
CYCLONE 2: A phase 3 study of abemaciclib with abiraterone in patients with metastatic castration-resistant prostate cancer.Org: Massachusetts General Hospital Cancer Center and Harvard Medical School, Institut Català d’Oncologia–Bellvitge Institute for Biomedical Research, Studienpraxis Urologie, Asan Medical Center, Hospital Universitario Gregorio Marañón,
Abstract
A randomised phase II multicentre study of ipilimumab with temozolomide vs temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: Ipi-Glio.Org: University College Hospital-London, The Christie Hospital NHS Foundation Trust, Guy's Hospital, Western General Hospital, Addenbrooke's Hospital,
Abstract
Final results from TACTI-002 Part C: A phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with metastatic 2nd line head and neck squamous cell carcinoma unselected for PD-L1.Org: Early Phase Clinical Trials Unit, START Madrid Fundacion Jimenez Diaz, Vall d’Hebron University Hospital/VHIO, Vall d’Hebron Institute of Oncology (VHIO), University College London Hospital NHS Trust and Great Ormond Street Hospital,
Abstract
Neoadjuvant immunotherapy with ipilimumab plus nivolumab and radiologically and pathologically quantifiable responses through modulation of the tumour microenvironment in resectable hepatocellular carcinoma.Org: Imperial College, Imperial College London, Imperial College, St Mary's Campus, Imperial College Healthcare NHS Trust, Barts and The London HPB Centre,